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Recent data have emerged from adoptive T-cell therapies
where exogenous expression of a chimeric antigen recep-
tor (CAR) has been shown to confer cancer recognition
on autologous T cells. However, the ability to apply this
technology in an allogeneic setting would permit the gen-
eration of universal “off the shelf” T cells that would
overcome many current technical and logistic hurdles
to the practical application of adoptive immunothera-
pies. Transcription Activator-Like Effector Nucleases
(TALENTM) can be used to inactivate the T cell recep-
tor (TCR) alpha gene, eliminating the TCR and thus
the potential of graft versus host disease (GVHD), one
of the major obstacles towards an allogeneic approach.
However, TCR disruption also results in the elimina-
tion of the CD3 signaling complex from the T-cell
surface, and thus may alter the cells ’ capacity for
expansion and/or survival. The pre-T cell receptor
(pre-TCR) is expressed by immature thymocytes and is
crucial for T cell development. Pre-TCR consists of an
invariant pre-T alpha chain, variable rearranged TCR
beta chains and CD3 signaling components. In contrast
to the TCR, which requires interaction with peptide-
loaded major histocompatibility complexes to initiate
T cell signaling, the pre-TCR is thought to signal
through a ligand-independent mechanism that occludes
TCR surfaces required for MHC interaction. Here we
demonstrate that the expression of the invariant pre-T
alpha chain, in the absence of TCR alpha, results in the
restoration of CD3 at the cell surface in association
with a pre-TCR. Cells with preTCR/CD3 complexes
have an improved life span, and can be expanded ex
vivo through standard CD3/CD28-based bead methods.
Application of this technology in association with allo-
geneic CAR modified T cells will also be presented.
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